Clinical Efficacy of INTRON® A (Interferon alfa-2b, recombinant) for Injection The goal of treatment for viral hepatitis is to eradicate the virus early in the course of the disease in order to prevent progression to end-stage liver disease. As the only indicated monotherapy for both chronic hepatitis B and C, interferon alfa-2b monotherapy can provide: Long-term sustained improvement in liver function Reduction of viral load Reduction of inflammation In controlled trials with HCV patients, INTRON® A: Reduced ALT levels to normal or significantly reduced ALT levels from baseline in 24 percent of patients receiving 18 to 24 months of therapy. Was associated with significant histological improvement in 58 percent of responding patients with extended therapy. Data show that INTRON A therapy for up to 24 months may double its efficacy, as shown in the following graph. ALT Response Rate vs. Duration of Therapy in Chronic Hepatitis C Patients                     *A sustained response was defined as a complete response at the end of the treatment period, with sustained normal ALT values lasting at least 6 months following discontinuation of therapy.   9 of 11 Terms and Conditions | Privacy Policy | Important Safety Information